Genelux (GNLX) Cash & Equivalents (2022 - 2026)

Genelux's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $9.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 32.61% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $9.3 million (down 32.61% YoY), while the FY2025 annual figure was $5.3 million, down 37.73% from the prior year.
• Cash & Equivalents was $9.3 million for Q1 2026 at Genelux, up from $5.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $40.0 million in Q2 2024 to a low of $397000.0 in Q4 2022.
• Historically, Cash & Equivalents has averaged $16.5 million across 5 years, with a median of $11.5 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents surged 1895.97% in 2023, then plunged 48.64% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $397000.0 in 2022, then soared by 1895.97% to $7.9 million in 2023, then increased by 8.09% to $8.6 million in 2024, then sank by 37.73% to $5.3 million in 2025, then soared by 74.39% to $9.3 million in 2026.
• The last three Cash & Equivalents figures came in at $9.3 million (Q1 2026), $5.3 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.